iCan CGM Pediatric Study Published in the Journal of Diabetes Science and Technology
Sinocare announced the publication of pivotal pediatric clinical data for its iCan continuous glucose monitoring (CGM) system in the Journal of Diabetes Science and Technology, a leading international peer-reviewed journal. The study reports an overall MARD of 8.89% in children and adolescents aged 2-17 years, with 100% of glucose readings falling within clinically acceptable error grid zones. This is the third peer-reviewed publication for the iCan CGM system and its first dedicated pediatric manuscript. DOI: 10.1177/19322968261463536
The prospective, multicenter study enrolled 78 pediatric participants with diabetes across three clinical centers in China. Subjects wore two sensors on the abdomen, with device accuracy assessed against a laboratory venous blood glucose reference (Biosen C-Line, EKF-diagnostic GmbH) at three time windows: Days 1-2, 7-9, and 15-16. In a conservative analytical approach, results were reported for the poorer-performing sensor.
Key Results:
①MARD: 8.89% overall, with stable single-digit accuracy across the full 15-day wear period (Days 1-2: 8.65%; Days 7-9: 8.70%; Days 15-16: 9.30%).
②Error grid: 100.00% of data pairs in Zones A+B on both Consensus and DTS error grid analyses.
③Alarm performance: True alarm rates of 98.6% for hypoglycemia and 98.8% for hyperglycemia.
④Wear durability: Mean sensor life of 14.4 days with 92.0% of sensors reaching the full 15-day target. No device-related or skin-related adverse events were reported.
The iCan CGM system uses third-generation sensor technology based on modified glucose dehydrogenase (GDH) with a flavin adenine dinucleotide (FAD) cofactor. With over 500 participants across six completed clinical studies conducted in the United States, Europe, and Asia, the iCan CGM system is one of the most extensively clinically studied CGM platforms worldwide.
Citation: Wang F, Flacke F, Ding S, Ouyang W, Wu H. Performance, Safety and Usability of a Third-Generation Continuous Glucose Monitoring System in a Pediatric Population: Results From a Prospective, Multicenter Study. J Diabetes Sci Technol. 2026.
DOI: https://doi.org/10.1177/19322968261463536
About Sinocare iCan CGM System
Sinocare iCan CGM System is one of the most widely clinically studied continuous glucose monitoring systems in the world.1, 2, 3, 4, 5
More than 500 people with type 1 and type 2 diabetes have participated in our world-wide clinical studies, and most clinical study participants have been assessed at sites in either the United States of America or in the Federal Republic of Germany. ~ 60.95% of 507 worldwide iCan CGM system clinical study subjects are people living with diabetes in either the USA or in Europe.
iCan CGM clinical study citations:
Enrolment n=159 https://clinicaltrials.gov/study/NCT05806554 a completed study in adults.(1)
Enrolment n=134 https://clinicaltrials.gov/study/NCT05908448 a completed study in children.(2)
DOI: https://doi.org/10.1177/19322968261463536.(3)
Enrolment n=16 https://clinicaltrials.gov/study/NCT05348928 a completed study in adults.(4)
DOI: https://doi.org/10.3969/j.issn.1006-6187.2026.05.004(5)
About Sinocare
Established in 2002, Sinocare is the first blood glucose meter company to be listed in China, and also the largest manufacturer of glucose monitoring devices in China. With a commercial presence in Asia, Europe and North America, Sinocare has expanded internationally through partnerships and acquisitions such as the USA based PTS Diagnostics Inc. and Trividia Health Inc., pioneering a digital management ecosystem for diabetes and chronic conditions by integrating “Biosensing + AI + Healthcare.” We provide global users and healthcare professionals with innovative products and smart medical solutions that seamlessly span prevention, monitoring, and long-term care. Today, our core portfolio comprises four strategic pillars: Personal Palm Labs, Precision Desktop Labs, Precision Wearable Systems, and Digital Diabetes Management Solutions.
Remaining steadfastly user-centric, Sinocare has built a global R&D and manufacturing infrastructure. By delivering accurate, easy-to-use, and affordable solutions, we break down the barriers of chronic disease management, bringing medical-grade diagnostics and digital health services into millions of households worldwide. By synergizing “AI Agents, Chronic Disease Expertise, and Continuous Behavioral Support,” Sinocare delivers an ecosystem of ongoing patient companionship, translating cutting-edge technology into tangible, life-changing health outcomes.